ImClone

2 Stories

Bristol-Myers Makes Bid for Icahn's ImClone

Offers 29% premium for biotech partner; shares soar

(Newser) - Already a 17% shareholder, Bristol-Myers Squibb laid down a $4.5 billion offer to buy the  rest of ImClone shares, the Wall Street Journal reports. The $60-a-share offer, sent to ImClone chairman Carl Icahn today, is a 29% premium on yesterday's closing price and makes Bristol the second pharma giant...

Genes ID Best Patients for Colon Cancer Drug

Step toward 'holy grail' of personalized cancer battle

(Newser) - Researchers have taken a giant step toward the "holy grail" of personalized cancer treatment—by using genetic profiling to accurately target chemotherapy, Reuters reports. A new genetic test of colon cancer tumors is able to predict with accuracy whether a patient will respond to treatment with the drug Erbitux,...

2 Stories